The immune systems of a large majority of people could already be primed to attack and possibly even disable a key component of CRISPR-Cas9 gene editing therapeutics (which are quickly moving towards their first human tests), suggests new research published today.
If this finding sounds familiar, it’s because another paper, posted in January before being peer reviewed, reached similar conclusions, plunging stock prices of CRISPR companies-CRISPR Therapeutics (NASDAQ CRSP), Editas Medicine (NASDAQ EDIT) and Intellia Therapeutics (NASDAQ NTLA).
Today’s paper, published in the peer-reviewed journal Nature Medicine, suggests those results from January weren’t a fluke…. Read more »
UNDERWRITERS AND PARTNERS